ISO-1
Based on 25 publication(s) in Google Scholar
ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM.
For research use only. We do not sell to patients.
- Purity: 99.84%
- CAS No.: 478336-92-4
- Formula: C12H13NO4
- Molecular Weight:235.24
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Clinical Compound Library
HY-L026
-
Human Metabolite Library
HY-L123
-
Macrophage Related Compound Library
HY-L174
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) ISO-1
More- Immunity. 2023 Oct 10;56(10):2325-2341.e15. [Abstract]
- Acta Pharm Sin B. 2025 Feb;15(2):1112-1125. [Abstract]
- Adv Sci (Weinh). 2026 May;13(25):e21265. [Abstract]
- Nat Cardiovasc Res. 2024 Apr 25:1-7.
- J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]
- J Transl Med. 2025 Nov 12;23(1):1273. [Abstract]
- J Invest Dermatol. 2026 Mar 24:S0022-202X(26)00998-X. [Abstract]
- J Invest Dermatol. 2024 May 30:S0022-202X(24)00384-1. [Abstract]
- Inflamm Res. 2025 Dec 17;75(1):4. [Abstract]
- Mol Ther Oncolytics. 2021 Aug 19:22:114-128. [Abstract]
- Commun Biol. 2025 Nov 18;8(1):1595. [Abstract]
- Inflammation. 2025 Dec 23;49(1):15. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 2):115901. [Abstract]
- Int Immunopharmacol. 2025 May 28:159:114959. [Abstract]
- Int Immunopharmacol. 2024 Aug 16:141:112891. [Abstract]
- Int Immunopharmacol. 2021 Jul:96:107555. [Abstract]
- Front Cell Dev Biol. 2021 Dec 31:9:791187. [Abstract]
- FASEB J. 2025 Oct 15;39(19):e71079. [Abstract]
- Exp Cell Res. 2024 May 11:114089. [Abstract]
- Food Chem Toxicol. 2023 Oct:180:114002. [Abstract]
- Mol Med Rep. 2019 Sep;20(3):2135-2142. [Abstract]
- PLoS One. 2023 Aug 24;18(8):e0288281. [Abstract]
- bioRxiv. 2026 Feb 12:2026.02.10.705129. [Abstract]
- bioRxiv. 2025 Feb 17.
- Research Square Preprint. 2023 Dec 27
Customer Validation & Images
-
In Vivo Imaging
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
WB
-
WB
Biological Activity
IC50: 7 μM (MIF)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| THP-1 | IC50 |
69 μM
Compound: iso-1
|
Inhibition of dopachrome tautomerase activity of MIF in human THP1 cells
Inhibition of dopachrome tautomerase activity of MIF in human THP1 cells
|
[PMID: 19592246] |
ISO-1 (0.1-20 μM; 16 hours) has a slight inhibitory effect on Cox-2 secretion without the addition of recombinant MIF[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7 macrophage cells
-
Concentration:0.1μM，1μM，10μM，20μM
-
Incubation Time:16 hours
-
Result:Suppressed Cox-2 secretion.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6 MIF+/+ and MIF–/– mice[2]
-
Dosage:3.5-35 mg/kg
-
Administration:Injected intraperitoneally; 3.5-35 mg/kg; twice a day ; 2 weeks
-
Result:Was protective against lethal sepsis.
-
Animal Model:Female C57BL/6-Tg(ACTB-EGFP)1Osb/J mice[3]
-
Dosage:35 mg/kg
-
Administration:Intraperitoneal injection; 35 mg/kg; twice daily; 3 days
-
Result:Reduced average endometriotic implant size.
Chemical Information
-
CAS No. 478336-92-4
-
Appearance Solid
-
Molecular Weight 235.24
-
Formula C12H13NO4
-
Color White to off-white
-
SMILES
O=C(OC)CC1ON=C(C(C=C2)=CC=C2O)C1
-
Synonyms
MIF Antagonist
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (25)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation. [Abstract]2023 Oct 10;56(10):2325-2341.e15. PMID: 37652021 -
Acta Pharm Sin B
NO-releasing double-crosslinked responsive hydrogels accelerate the treatment and repair of ischemic stroke. [Abstract]2025 Feb;15(2):1112-1125. PMID: 40177574 -
Adv Sci (Weinh)
Pancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma. [Abstract]2026 May;13(25):e21265. PMID: 41722056 -
-
J Neuroinflammation
New insights into meningitic Escherichia coli infection of brain microvascular endothelial cells from quantitative proteomics analysis. [Abstract]2018 Oct 19;15(1):291. PMID: 30340642
ISO-1 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]
ISO-1 treatment partially recovers PCN033- or RS218-mediated downregulation of the tight junction proteins ZO-1 and occludin.
ISO-1 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291. [Abstract]
ISO-1 treatment partially recovers PCN033- or RS218-mediated downregulation of the tight junction proteins ZO-1 and occludin.
-
J Transl Med
Metformin protects against cyclophosphamide-induced ovarian fibrosis by MIF/CD74-mediated macrophage polarization. [Abstract]2025 Nov 12;23(1):1273. PMID: 41225611 -
J Invest Dermatol
Dendritic cells remodel eccrine sweat gland niche metabolism through oxidative phosphorylation during aging. [Abstract]2026 Mar 24:S0022-202X(26)00998-X. PMID: 41887396 -
J Invest Dermatol
TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. [Abstract]2024 May 30:S0022-202X(24)00384-1. PMID: 38823435 -
Inflamm Res
Target Fibroblast-B cell crosstalk via MIF signaling drives pathogenic B cell differentiation and joint damage in knee osteoarthritis. [Abstract]2025 Dec 17;75(1):4. PMID: 41407905 -
Mol Ther Oncolytics
Exosome-mediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3K/AKT axis in gliomas. [Abstract]2021 Aug 19:22:114-128. PMID: 34514093
ISO-1 purchased from MedChemExpress. Usage Cited in: Mol Ther Oncolytics. 2021 Aug 19:22:114-128. [Abstract]
U87TR/luciferase cells were orthotopically implanted into the brains of BALB/c mice. DMSO, ISO-1 (5 mg/kg), LY294002, or ISO+LY294002 were injected (i.p.) into the mice twice per week for 28 days. Representative pseudocolor bioluminescence images of orthotopic tumors were obtained.
ISO-1 purchased from MedChemExpress. Usage Cited in: Mol Ther Oncolytics. 2021 Aug 19:22:114-128. [Abstract]
Kaplan-Meier survival curves of mice with different treatments. U87TR/luciferase cells were orthotopically implanted into the brains of BALB/c mice. DMSO, ISO-1 (5 mg/kg), LY294002, or ISO+LY294002 were injected (i.p.) into the mice twice per week for 28 days.
ISO-1 purchased from MedChemExpress. Usage Cited in: Mol Ther Oncolytics. 2021 Aug 19:22:114-128. [Abstract]
Representative H&E staining for tumor cytostructures. U87TR/luciferase cells were orthotopically implanted into the brains of BALB/c mice. DMSO, ISO-1 (5 mg/kg), LY294002, or ISO+LY294002 were injected (i.p.) into the mice twice per week for 28 days.
-
Commun Biol
MIF downregulation attenuates neuroinflammation via TLR4/MyD88/TRAF6/NF-κB pathway to protect dopaminergic neurons in Parkinson's disease model. [Abstract]2025 Nov 18;8(1):1595. PMID: 41254084 -
Inflammation
2025 Dec 23;49(1):15. PMID: 41436686 -
Int Immunopharmacol
Obacunone inhibits RIPK1/RIPK3/MLKL-mediated necroptosis by suppressing mitochondrial ROS and MIF signaling in intestinal ischemia-reperfusion injury. [Abstract]2026 Jan 1;168(Pt 2):115901. PMID: 41317539 -
Int Immunopharmacol
MIF regulates T helper 17 cell differentiation by activating the p38 MAPK signaling pathway to drive the pathogenesis of EAP. [Abstract]2025 May 28:159:114959. PMID: 40440956 -
Int Immunopharmacol
MIF aggravates experimental autoimmune prostatitis through activation of the NLRP3 inflammasome via the PI3K/AKT pathway. [Abstract]2024 Aug 16:141:112891. PMID: 39153310 -
Int Immunopharmacol
MIF inhibitor ISO-1 alleviates severe acute pancreatitis-associated acute kidney injury by suppressing the NLRP3 inflammasome signaling pathway. [Abstract]2021 Jul:96:107555. PMID: 33823428 -
Front Cell Dev Biol
Exosomal MIF Derived From Nasopharyngeal Carcinoma Promotes Metastasis by Repressing Ferroptosis of Macrophages. [Abstract]2021 Dec 31:9:791187. PMID: 35036405 -
FASEB J
MIF Promotes Phenotypic Switching of VSMCs via AKT/mTOR-Mediated Autophagy Regulation in Aortic Dissection. [Abstract]2025 Oct 15;39(19):e71079. PMID: 41001812 -
Exp Cell Res
MIF inhibition attenuates intervertebral disc degeneration by reducing nucleus pulposus cell apoptosis and inflammation. [Abstract]2024 May 11:114089. PMID: 38740166 -
Food Chem Toxicol
The crosstalk between M1 macrophage polarization and energy metabolism disorder contributes to polystyrene nanoplastics-triggered testicular inflammation. [Abstract]2023 Oct:180:114002. PMID: 37634612 -
Mol Med Rep
Protective effect of ISO‑1 against advanced glycation end product aggravation of PC12 cell injury induced by Aβ1‑40. [Abstract]2019 Sep;20(3):2135-2142. PMID: 31322215 -
PLoS One
Human embryonic stem cells secrete macrophage migration inhibitory factor: A novel finding. [Abstract]2023 Aug 24;18(8):e0288281. PMID: 37616250 -
bioRxiv
Characterizing the SASP-Dependent Paracrine Spreading of Senescence Between Human Brain Cell Types. [Abstract]2026 Feb 12:2026.02.10.705129. PMID: 41726875 -
-
Solvent & Solubility
Ethanol : 100 mg/mL (425.10 mM; Need ultrasonic)
DMSO : 50 mg/mL (212.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.63 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.63 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (42.51 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lubetsky JB, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82. [Content Brief]
[2]. Al-Abed Y, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem. 2005 Nov 4;280(44):36541-4. [Content Brief]
[3]. Nothnick WB, et al. Inhibition of macrophage migration inhibitory factor reduces endometriotic implant size in mice with experimentally induced disease. J Endometr. 2011 Sep 30;3(3):135-142. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 4.2510 mL | 21.2549 mL | 42.5098 mL | 106.2744 mL |
| 5 mM | 0.8502 mL | 4.2510 mL | 8.5020 mL | 21.2549 mL | |
| 10 mM | 0.4251 mL | 2.1255 mL | 4.2510 mL | 10.6274 mL | |
| 15 mM | 0.2834 mL | 1.4170 mL | 2.8340 mL | 7.0850 mL | |
| 20 mM | 0.2125 mL | 1.0627 mL | 2.1255 mL | 5.3137 mL | |
| 25 mM | 0.1700 mL | 0.8502 mL | 1.7004 mL | 4.2510 mL | |
| 30 mM | 0.1417 mL | 0.7085 mL | 1.4170 mL | 3.5425 mL | |
| 40 mM | 0.1063 mL | 0.5314 mL | 1.0627 mL | 2.6569 mL | |
| 50 mM | 0.0850 mL | 0.4251 mL | 0.8502 mL | 2.1255 mL | |
| 60 mM | 0.0708 mL | 0.3542 mL | 0.7085 mL | 1.7712 mL | |
| 80 mM | 0.0531 mL | 0.2657 mL | 0.5314 mL | 1.3284 mL | |
| 100 mM | 0.0425 mL | 0.2125 mL | 0.4251 mL | 1.0627 mL |
Powered by Bioz